Literature DB >> 16240724

[Down-regulation of TRIP6 expression induces actin cytoskeleton rearrangements in human carcinoma cell lines].

O A Gur'ianova, A A Sablina, P M Chumakov, E I Frolova.   

Abstract

Structure and dynamics of actin cytoskeleton play a role ih regulation of cell adhesion, spreading and migration. TRIP6 is a LIM domain-containing protein interacting with many actin-associated proteins and in addition modulating activity of certain transcription factors. To study functions of TRIP6 we inhibited its expression in A549 and A431 cells by short interfering RNAs (siRNAs). The TRIP6 knock-down lead to the increased number and length of stress fibers and to the induction of locomotive phenotype. There was observed decreased number and reorganization of focal adhesions revealed by staining for paxillin, and loss of cell to cell adhesions revealed by staining for E-cadherin. The above changes in cell morphology were accompanied by 2-fold increase in the cell motility rate assessed by the wound healing assay. Thus, down-regulation of TRIP6 in the cell lines used results in increase in the features characteristic to malignant transformation of epithelial cells. Possible mechanisms for the observed effects are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16240724      PMCID: PMC2773822     

Source DB:  PubMed          Journal:  Mol Biol (Mosk)        ISSN: 0026-8984


  23 in total

1.  The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL.

Authors:  E Cuppen; M van Ham; D G Wansink; A de Leeuw; B Wieringa; W Hendriks
Journal:  Eur J Cell Biol       Date:  2000-04       Impact factor: 4.492

Review 2.  Functions of the adapter protein Cas: signal convergence and the determination of cellular responses.

Authors:  A H Bouton; R B Riggins; P J Bruce-Staskal
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

3.  LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains.

Authors:  Y Wang; T D Gilmore
Journal:  Biochim Biophys Acta       Date:  2001-04-23

Review 4.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

Review 5.  Killing the messenger: short RNAs that silence gene expression.

Authors:  Derek M Dykxhoorn; Carl D Novina; Phillip A Sharp
Journal:  Nat Rev Mol Cell Biol       Date:  2003-06       Impact factor: 94.444

6.  A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters.

Authors:  Olivier Kassel; Sandra Schneider; Christine Heilbock; Margarethe Litfin; Martin Göttlicher; Peter Herrlich
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

7.  LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor.

Authors:  M K Zhao; Y Wang; K Murphy; J Yi; M C Beckerle; T D Gilmore
Journal:  Gene Expr       Date:  1999

8.  Members of the Zyxin family of LIM proteins interact with members of the p130Cas family of signal transducers.

Authors:  Jinseong Yi; Susanne Kloeker; Christopher C Jensen; Susanne Bockholt; Hiroaki Honda; Hisamura Hirai; Mary C Beckerle
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

9.  The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain.

Authors:  K S Erdmann; J Kuhlmann; V Lessmann; L Herrmann; V Eulenburg; O Müller; R Heumann
Journal:  Oncogene       Date:  2000-08-10       Impact factor: 9.867

Review 10.  The protein tyrosine phosphatase PTP-Basophil/Basophil-like. Interacting proteins and molecular functions.

Authors:  Kai S Erdmann
Journal:  Eur J Biochem       Date:  2003-12
View more
  6 in total

1.  Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.

Authors:  Xiaobing Miao; Xiaohong Xu; Yaxun Wu; Xinghua Zhu; Xudong Chen; Chunsun Li; Xiaoyun Lu; Yali Chen; Yushan Liu; Jieyu Huang; Yuchan Wang; Song He
Journal:  Tumour Biol       Date:  2015-08-23

2.  Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.

Authors:  Markus Diefenbacher; Sylwia Sekula; Christine Heilbock; Jana V Maier; Margarethe Litfin; Hans van Dam; Marc Castellazzi; Peter Herrlich; Olivier Kassel
Journal:  Mol Endocrinol       Date:  2008-06-05

3.  CRISPR/Cas9-mediated Genomic Editing of Cluap1/IFT38 Reveals a New Role in Actin Arrangement.

Authors:  Tina Beyer; Sylvia Bolz; Katrin Junger; Nicola Horn; Muhammad Moniruzzaman; Yasmin Wissinger; Marius Ueffing; Karsten Boldt
Journal:  Mol Cell Proteomics       Date:  2018-04-03       Impact factor: 5.911

4.  Characterization of TRIP6-dependent nasopharyngeal cancer cell migration.

Authors:  Jie Fei; Jihong Li; Sunan Shen; Weidong Zhou
Journal:  Tumour Biol       Date:  2013-04-11

5.  DNA methylation analysis of negative pressure therapy effect in diabetic foot ulcers.

Authors:  A H Ludwig-Slomczynska; S Borys; M T Seweryn; J Hohendorff; P Kapusta; B Kiec-Wilk; E Pitera; P P Wolkow; M T Malecki
Journal:  Endocr Connect       Date:  2019-11       Impact factor: 3.335

6.  Simultaneous analysis of distinct Omics data sets with integration of biological knowledge: Multiple Factor Analysis approach.

Authors:  Marie de Tayrac; Sébastien Lê; Marc Aubry; Jean Mosser; François Husson
Journal:  BMC Genomics       Date:  2009-01-20       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.